• Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value.
• The stock last closed at US$60.66, with returns of 117.0% over 7 days, 265.6% over 30 days and 260.2% year to date. The 1 year and 3 year returns stand at negative 24.6% and negative 90.4% respectively.
• These sharp moves are drawing attention back to agilon health, especially as investors weigh the recent price action against a longer history that includes a 5 year return of negative 91.7%. With that mix of short term strength and longer term weakness, the key question is whether the current valuation is now stretched or still reflecting caution.
• agilon health currently has a valuation score of 3/6, which means it screens as undervalued on half of Simply Wall St’s checks. The next sections will walk through the standard valuation approaches investors often use, before finishing with a way to look at value that goes beyond the usual ratios and models.

Approach 1: agilon health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting future cash flows and discounting them back to the present.

For agilon health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at a loss of about $90.1 million. Analyst and extrapolated projections move from a projected free cash flow of $104.6 million loss in 2026 to projected positive free cash flow of $36.4 million in 2030, all expressed in US$ and remaining below the billion range.

Simply Wall St aggregates these projections, discounts each year’s cash flow, and arrives at an estimated intrinsic value of about $31.84 per share for agilon health. Compared to a recent share price of $60.66, the model implies the stock is about 90.5% above this DCF estimate. This points to a rich valuation on this metric alone.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests agilon health may be overvalued by 90.5%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: agilon health Price vs Sales (P/S)

For companies where earnings are limited or volatile, the P/S ratio can be a useful way to think about value because it compares what investors are paying to the revenue the business generates, rather than to earnings that may be temporarily depressed.

In general, higher expected growth and lower perceived risk can justify a higher “normal” P/S multiple, while slower growth and higher risk tend to support a lower multiple. That context helps when you compare a stock’s current P/S to its industry and peers.

agilon health currently trades on a P/S ratio of 0.17x. This sits below the Healthcare industry average P/S of 1.21x and below the peer group average of 2.18x. Simply Wall St’s Fair Ratio for agilon health is 0.33x, which is its proprietary estimate of what the P/S could be given factors such as the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for growth, risks, profitability, sector and size, rather than assuming all companies deserve the same multiple. Comparing agilon health’s Fair Ratio of 0.33x with its actual 0.17x P/S suggests the stock screens as undervalued on this measure.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your agilon health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your own story for agilon health that links what you believe about its future revenue, earnings and margins to a financial forecast, a Fair Value, and then a clear comparison with the current price. All of this is provided within an easy tool on Simply Wall St's Community page that updates when new information like earnings or news arrives. One investor might side with a cautious view closer to a US$6.25 Fair Value, while another leans toward a more optimistic stance nearer US$37.50, and each can see how their assumptions translate into a personal decision-making framework without having to build a full model from scratch.

Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.